Microban and Cleanwaste Medical Unveil the new Sani-Bag+ with Built-in Antimicrobial Technology

Microban International is pleased to unveil a new partnership with Cleanwaste Medical to develop the Sani-Bag+ with built-in Microban® antimicrobial product protection. This industry-leading antimicrobial technology helps to protect the commode and bedpan liners from the growth of odor-causing bacteria, and complements Cleanwaste Medical’s proprietary formulation of deodorizing technology and NASA-developed absorbent gel polymer to create waste management solutions that are cleaner and more discreet.

The Sani-Bag+ has been meticulously designed and engineered with Microban technology to address the pressing need for clean and user-friendly disposable commode and bedpan liners in healthcare settings. The addition of innovative Microban® antimicrobial technology sets a new industry standard, further elevating the functionality of these bags to provide a fresher, more comfortable and more dignified experience for the user.

Michael Ruby, President at Microban International, commented:

“Microban is extremely proud of its partnership with Cleanwaste Medical, which brings together the expertise of both companies to deliver a practical and reliable solution for clean waste management. With over 30 years of industry leading experience, Microban’s antimicrobial technologies enhance the cleanliness of these liners by helping to prevent the growth of bacteria, ensuring fresher, cleaner and more convenient solutions for consumers and professionals.”

Sam Alhmad, National Sales Manager at Cleanwaste Medical added:

“We are very excited to partner with a trusted company of Microban’s caliber, and develop a line of antimicrobial Sani-Bag+ products that truly fulfill an unmet need, setting us apart from our competitors. These bags have been carefully designed to deliver a solution with enhanced antimicrobial performance that revolutionizes the user experience and is easily disposed of to prevent contact with waste. Microban® antimicrobial product protection is the perfect addition to these products, marrying up with our proprietary odor-neutralizing and waste absorbance technologies to make these liners the go-to choice for healthcare settings.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy